Brokerages Set Bio-Rad Laboratories (BIO) PT at $297.20

Bio-Rad Laboratories (NYSE:BIO) has been given a consensus recommendation of “Buy” by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $297.20.

A number of equities analysts recently issued reports on the stock. ValuEngine raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Wells Fargo dropped their target price on shares of Bio-Rad Laboratories from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Citigroup boosted their target price on shares of Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. CL King lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a research report on Friday, February 16th. Finally, Jefferies Group boosted their target price on shares of Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th.

How to Become a New Pot Stock Millionaire

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can boosted its stake in Bio-Rad Laboratories by 12.8% during the fourth quarter. Bank of Montreal Can now owns 18,201 shares of the medical research company’s stock worth $4,343,000 after buying an additional 2,061 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth $2,029,000. JPMorgan Chase & Co. boosted its stake in Bio-Rad Laboratories by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 30,855 shares of the medical research company’s stock worth $6,861,000 after buying an additional 5,823 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Bio-Rad Laboratories by 8.4% during the third quarter. Janus Henderson Group PLC now owns 36,310 shares of the medical research company’s stock worth $8,069,000 after buying an additional 2,800 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bio-Rad Laboratories by 42.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock worth $278,000 after buying an additional 350 shares in the last quarter. 64.52% of the stock is currently owned by institutional investors and hedge funds.

NYSE:BIO opened at $262.13 on Friday. Bio-Rad Laboratories has a 12 month low of $201.90 and a 12 month high of $279.59. The company has a market capitalization of $7,353.25, a PE ratio of 63.93, a PEG ratio of 2.87 and a beta of 0.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.93.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.28 by $0.22. Bio-Rad Laboratories had a net margin of 5.31% and a return on equity of 3.63%. The business had revenue of $620.43 million for the quarter, compared to analyst estimates of $618.89 million. analysts predict that Bio-Rad Laboratories will post 5.73 earnings per share for the current fiscal year.

WARNING: “Brokerages Set Bio-Rad Laboratories (BIO) PT at $297.20” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://weekherald.com/2018/04/17/brokerages-set-bio-rad-laboratories-bio-pt-at-297-20.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Analyst Recommendations for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply